Charles River delivers solutions for your biosimilar testing and manufacturing programs. A development program consisting of analytical and bioanalytical assays, pharmacology and/or toxicology studies in animals and clinical trials is required to show that biosimilars are highly similar to the reference biologic product. Our experience working with biologics across the drug development continuum, combined with our regulatory expertise, means we are an ideal partner for your biosimilar development.

Biosimilar Webinar Series Replay

Experts elaborate on aspects of biosimilar development such as potency determination, structural characterization and bioanalytical assay requirements. Watch »

Since the development and manufacturing of biosimilars can be just as complex as the innovator products, it is important to find a provider that has experience with various types of molecules.

Below are examples of molecules that Charles River has worked with:

Hormones: Erythropoietin, Teriparatide, Parathyroid hormone
Cytokines: Pegfilgrastim, Filgrastim, Molgramostim

Other: Etanercept

*Log in to the Source to access this document.

You may also be interested in...

Outsourcing Biosimilar Development

A rapid increase in the number of companies working on the development and registration of biosimilars has created a significant market for outsourced services specific to these products. Niall Dinwoodie discusses this in BioProcess International.

ADCP: Improving Bioassay Reproducibility

In this BioProcessing Journal article, Dr. Ulrike Herbrand summarizes a number of challenges associated with antibody-dependent cellular phagocytosis (ADCP) assays and discusses how novel approaches are more reliable in measuring this neglected mechanism of action.

The Analytical Challenges of the Biosimilar Boom

With the acceleration in the development of biosimilars, we are starting to see an imbalance in the industry. This will manifest in several ways, including financial, market competition, innovation and geographic redistribution. As a result, the biologics industry is due for substantial changes.